Literature DB >> 7540863

Human vascular endothelial cells process and present autoantigen to human T cell lines.

C O Savage1, C J Brooks, G C Harcourt, J K Picard, W King, D M Sansom, N Willcox.   

Abstract

The effectiveness of cultured human umbilical vein endothelial cells as accessory cells for T cell activation has been investigated using T cell clones and lines derived from patients with myasthenia gravis which were specific for different epitopes on the alpha subunit of the human acetylcholine receptor. The endothelial cells were induced with IFN-gamma to express HLA-DR and -DQ at high and low levels respectively. They could then efficiently present specific peptides of the alpha subunit to an HLA-DR- and an HLA-DQw5-restricted T cell line. They could also process epitopes for both T cell lines from the full-length recombinant alpha subunit (r1-437) of the human acetylcholine receptor, where the known epitopes are 80 amino acid residues apart. The endothelial presentation of r1-437, but not of the peptides, was sensitive to chloroquine inhibition. Presentation appeared slightly less efficient (by 1.5- to 3.0-fold) with endothelial cells than with presenting cells from peripheral blood. This may reflect differences in accessory signalling since mAb blocking studies suggested that ligands for CD28 provided important accessory signalling by peripheral blood presenting cells while LFA-3 was used by endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540863     DOI: 10.1093/intimm/7.3.471

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  16 in total

Review 1.  Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.

Authors:  S E Burastero; G A Rossi
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.

Authors:  Jaehyuk Choi; Jason Walker; Sergei Boichuk; Nancy Kirkiles-Smith; Nicholas Torpey; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells.

Authors:  A C Cunningham; J G Zhang; J V Moy; S Ali; J A Kirby
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

Review 4.  Participation of blood vessel cells in human adaptive immune responses.

Authors:  Jordan S Pober; George Tellides
Journal:  Trends Immunol       Date:  2011-10-24       Impact factor: 16.687

5.  ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells.

Authors:  Saman Khayyamian; Andreas Hutloff; Kerstin Büchner; Michael Gräfe; Volker Henn; Richard A Kroczek; Hans W Mages
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

Review 6.  Invadosomes are coming: new insights into function and disease relevance.

Authors:  Elyse K Paterson; Sara A Courtneidge
Journal:  FEBS J       Date:  2017-06-22       Impact factor: 5.542

Review 7.  Infection of the endothelium by members of the order Rickettsiales.

Authors:  Gustavo Valbuena; David H Walker
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

Review 8.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

9.  Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes.

Authors:  Jason D Walker; Cheryl L Maier; Jordan S Pober
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

10.  T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor.

Authors:  Peter Newton; Graeme O'Boyle; Yvonne Jenkins; Simi Ali; John A Kirby
Journal:  Mol Immunol       Date:  2009-09-20       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.